IMMUNESENSOR THERAPEUTICS
ImmuneSensor Therapeutics is a biotechnology company that develops novel medicines for the treatment of cancer and other autoimmune diseases. Dedicated to developing new medicines that use the body's innate immune system to cure a variety of diseases.
IMMUNESENSOR THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2019-01-01
Address:
Dallas, Texas, United States
Country:
United States
Website Url:
http://www.immunesensor.com
Total Employee:
1+
Status:
Active
Contact:
+1 469 757 5110
Email Addresses:
[email protected]
Similar Organizations
AcureX Therapeutics
AcureX Therapeutics is a biotechnology company.
Geneius
Geneius is a Biotechnology company.
Rekindle Therapeutics
Rekindle Therapeutics is a biotechnology company.
Current Advisors List
Current Employees Featured
Founder
Official Site Inspections
http://www.immunesensor.com
- Host name: ec2-34-192-255-123.compute-1.amazonaws.com
- IP address: 34.192.255.123
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "ImmuneSensor Therapeutics"
About Us | ImmuneSensor Therapeutics
Our History Pioneers of cGAS/cGAMP. ImmuneSensor was founded in 2014 based on the seminal research conducted in the laboratory of Dr. Zhijian “James” Chen's at the University of Texas Southwestern Medical Center. In 2012, his …See details»
ImmuneSensor Therapeutics - Crunchbase Company …
ImmuneSensor Therapeutics is a biotechnology company that develops novel medicines for the treatment of cancer and other autoimmune diseases. It is dedicated to developing new medicines that use the body's innate immune …See details»
ImmuneSensor Therapeutics - PitchBook
ImmuneSensor Therapeutics General Information Description. Developer of novel medicines designed to harness innate immunity to treat cancer and autoimmune diseases. The company develops medicines that target pathways to modulate …See details»
ImmuneSensor Therapeutics Company Profile - Office Locations
ImmuneSensor Therapeutics is a company aiming to treat cancer and autoimmune diseases. It develops medicines that target the cGAS (cyclic GMP-AMP synthase) – STING (stimulator of …See details»
ImmuneSensor Therapeutics - Funding, Financials, Valuation
ImmuneSensor Therapeutics is a biotechnology company that develops novel medicines for the treatment of cancer and other diseases. Search Crunchbase. Start Free Trial . Chrome …See details»
Press Release | ImmuneSensor Therapeutics
Nov 20, 2024 ImmuneSensor is developing IMSB301 initially in cGAS-driven Type I interferonopathies including AGS, as well as CLE and selected patient populations with SLE. …See details»
ImmuneSensor Therapeutics Initiates Dosing in Phase 1
Aug 10, 2024 ImmuneSensor is a privately held, clinical stage company founded on the groundbreaking discovery of cGAS and cGAMP along with their combined role in regulating …See details»
ImmuneSensor Therapeutics - VentureRadar
" ImmuneSensor Therapeutics is developing novel medicines that target the cGAS (cyclic GMP-AMP synthase) – STING (stimulator of interferon genes) pathway to modulate the innate …See details»
ImmuneSensor Therapeutics Receives Orphan Drug and Rare …
Nov 20, 2024 ImmuneSensor is dedicated to developing best-in-class small molecule inhibitors of the cGAS-STING signaling pathway to potentially address therapeutic areas with significant …See details»
ImmuneSensor Awarded $16 Million Grant from the Cancer
Sep 20, 2022 ImmuneSensor Therapeutics Inc. (“ImmuneSensor”) is a private clinical stage biotechnology company dedicated to harnessing innate immunity to treat cancer and …See details»
ImmuneSensor Therapeutics Receives Orphan Drug and Rare …
Nov 20, 2024 ImmuneSensor Therapeutics. Company is evaluating IMSB301 in a Phase 1 clinical trial in healthy volunteers and plans to move rapidly into Phase 1b/2 clinical studies in …See details»
ImmuneSensor Therapeutics Receives Orphan Drug and Rare
Nov 20, 2024 ImmuneSensor is a privately held, clinical stage company founded on the groundbreaking discovery of cGAS and cGAMP along with their combined role in regulating …See details»
ImmuneSensor Awarded $16 Million Grant from the Cancer
Sep 20, 2022 ImmuneSensor Therapeutics Inc. announced the Company has been awarded a $16.1 million Product Development Research Grant from the Cancer Prevention and Research …See details»
ImmuneSensor Therapeutics Granted New U.S. Patent for its
Sep 17, 2024 ImmuneSensor is a privately held, clinical stage company founded on the groundbreaking discovery of cGAS and cGAMP along with their combined role in regulating …See details»
ImmuneSensor Therapeutics Receives Clearance from
Aug 19, 2024 ImmuneSensor is a privately held, clinical stage company founded on the groundbreaking discovery of cGAS and cGAMP along with their combined role in regulating …See details»
ImmuneSensor Therapeutics Receives Clearance from Australian …
Aug 19, 2024 ImmuneSensor is a privately held, clinical stage company founded on the groundbreaking discovery of cGAS and cGAMP along with their combined role in regulating …See details»
News | ImmuneSensor Therapeutics
Sep 16, 2024 ImmuneSensor Therapeutics Granted New U.S. Patent for its Oral cGAS Inhibitors . September 16, 2024 ImmuneSensor Therapeutics to Participate in the UBS 2024 Virtual …See details»
Press Release | ImmuneSensor Therapeutics
Oct 8, 2024 ImmuneSensor is a privately held, clinical stage company founded on the groundbreaking discovery of cGAS and cGAMP along with their combined role in regulating …See details»
Publications | ImmuneSensor Therapeutics
Latest Publications. Tumor-targeted Delivery of a STING Agonist Improves Cancer Immunotherapy. Wu Y-T, Fang, Y, Wei, Q et al.. PNAS 2022 119(49) : E2214278119.See details»